Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells

Oncogene

Volumn 26, Issue 8, 2007, Pages 1166-1177

  Pickering, B M ^a   De Mel, S ^a   Lee, M ^a   Howell, M ^a   Habens, F ^a   Dallman, C L ^a   Neville, L A ^a   Potter, K N ^a   Mann, J ^b   Mann, D A ^b   Johnson, P W M ^a   Stevenson, F K ^a   Packham, G ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Chronic lymphocytic leukaemia; NF B; Nuclear factor kappa B

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE 3; CASPASE 9; CD38 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 16; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN C JUN; PROTEIN KINASE ZAP 70; PROTEIN MCL 1;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MITOCHONDRIAL MEMBRANE; NUCLEOTIDE SEQUENCE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CASPASE 3; CASPASE 9; CELL NUCLEUS; CELL SURVIVAL; DITERPENES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MAP KINASE KINASE 4; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; NITRILES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 33847185843     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209897     Document Type: Article

References (58)

1. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC et al. (2001). Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98: 3050-3057.
2. Brenner C, Le Bras M, Kroemer G. (2003). Insights into the mitochondrial signaling pathway: what lessons for chemotherapy? J Clin Immunol 23: 73-80.
3. Caligaris-Cappio F, Hamblin TJ. (1999). B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17: 399-408.
4. Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ et al. (2005). ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106: 2506-2512.
5. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L et al. (2005). ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105: 2036-2041.
6. Claudio E, Brown K, Park S, Wang H, Siebenlist U. (2002). BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3: 958-965.
7. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. (2003). ZAP-70 expression as a surrogate for immunoglobulin-variable- region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 764-775.
8. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM et al. (2004). A sustained activation of P13K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18: 1391-1400.
9. Dallman C, Packham G. (2005). Purification of primary malignant B-cells and immunoblot analysis of bcl-2 family proteins. Methods Mol Med 115: 1-13.
10. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. (1999). IgVgene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
11. DeMeester SL, Buchman TG, Qiu Y, Dunnigan K, Hotchkiss RS, Karl IE et al. (1998). Pyrrolidine dithiocarbamate activates the heat shock response and thereby induces apoptosis in primed endothelial cells. Shock 10: 1-6.
12. Feuillard J, Schuhmacher M, Kohanna S, Asso-Bonnet M, Ledeur F, Joubert-Caron R et al. (2000). Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 95: 2068-2075.
13. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. (2000). Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164: 2200-2206.
14. Ghia P, Caligaris-Cappio F. (2000). The indispensable roll of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 79: 157-173.
15. Grad JM, Zeng XR, Boise LH. (2000). Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 12: 543-549.
16. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al. (2001). Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97: 2777-2783.
17. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. (1999). Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854.
18. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK et al. (2002). CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99: 1023-1029.
19. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. (2002). Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201-205.
20. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM et al. (2002). BAFF/BlyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-KappaB2. Immunity 17: 515-524.
21. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V et al. (2004). Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-688.
22. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. (1998). The inhibitors of apoptosis (LAPs) and their emerging role in cancer. Oncogene 17: 3247-3259.
23. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. (1999). NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96: 9136-9141.
24. Lee JH, Koo TH, Hwang BY, Lee JJ. (2002). Kaurane diterpene, kamebakaurin, inhibits NF-kappa B by directly targeting the DNA-binding activity of p50 andblocks the expression of antiapoptotic NF-kappa B target genes. J Biol Chem 277: 18411-18420.
25. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y et al. (2003). Large-scale identification and characterization of human genes that activate NF-kappaB and MARK signaling pathways. Oncogene 22: 3307-3318.
26. Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M et al. (2004). Ncl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 23: 4818-4827.
27. Morabito F, Mangiola M, Oliva B, Stelitano C, Callea V, Deaglio S et al. (2001). Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leukemia Res 25: 927-932.
28. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Dohner H. (2002). Tumour necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 100: 3749-3756.
29. Natoli G, Saccani S, Bosisio D, Marazzi I. (2005). Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol 6: 439-445.
30. Oakley F, Mann J, Ruddell RG, Pickford J, Weinmaster G, Mann DA. (2003). Basal expression of IkappaBalpha is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notch1. J Biol Chem 278: 24359-24370.
31. Orlowski RZ, Baldwin Jr AS. (2002). NF-kappa B as a therapeutic target in cancer. Trends Mol Med 8: 385-389.
32. Packham G, Stevenson FK. (2005). Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114: 441-449.
33. Packham G, Brimmell M, Cleveland JL. (1997). Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J 328: 807-813.
34. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. (2004). Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 117: 5197-5208.
35. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al. (2002). Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100: 1795-1801.
36. Pepper C, Thomas A, Hoy T, Cotter F, Bentley P. (1999). Antisense-mediated suppression of Bcl-2 highlights its pivotol role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 107: 611-615.
37. Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S et al. (2005). Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 105: 4820-4827.
38. Perkins ND. (2004). NF-kappa B: tumour promoter or suppressor? Trends Cell Biol 14: 64-69.
39. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T et al. (1997). Novel inhibitors of cytokine-induced Ikappa Balpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 12103-21096.
40. Ran R, Lu A, Zhang L, Tang Y, Zhu H, Xu H et al. (2004). Hsp70 promotes TNF-mediated apoptosis by binding IKK, gamma and impairing NF-kappaB survival signaling. Genes Dev 18: 1466-1481.
41. Ravid T, Hochstrasser M. (2004). NF-kappaB signaling flipping the switch with polyubiquitin chains. Curr Biol 14: R898-R900.
42. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. (2002). Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL association with protein kinase Cdelta. Blood 100: 3741-3748.
43. Rodriguez A, Martinez N, Camacho FI, Ruiz-Ballesteros E, Algara P, Garcia JF et al. (2004). Variability in the degree of expression of phosphorylated Ikappa Balpha in chronic lymphocytic leukemia cases with nodial involvement. Clin Cancer Res 10: 6796-6806.
44. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F et al. (1998). Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92: 990-995.
45. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. (2001). Relation of gene expression phenotype to immunoglobulin mutation genotype in Bcell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647.
46. Rossi A, Elia G, Santoro MG. (1998). Activation of the heatshock factor 1 by serine protease inhibitors. An effect associated with nuclear factor-kappaB inhibition. J Biol Chem 273: 16446-16452.
47. Sembries S, Pahl H, Stilgenbauer S, Dohner H, Schriever F. (1999). Reduced expression of adhesion molecules andcell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 93: 624-631.
48. Shaffer AL, Rosenwald A, Staudt LM. (2002). Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-932.
49. Schattner EJ. (2000). CD40 ligand in CLL pathogenesis and therapy. Leukemia Lymphoma 37: 461-472.
50. Schmitz ML, Mattioli I, Buss H, Kracht M. (2004). NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 5: 348-358.
51. Scorrano L, Korsmeyer SJ. (2003). Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 304: 437-444.
52. Takayama S, Reed JC. (2001). Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 3: E237-E241.
53. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. (2005). The tumour necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14(Fn14) signaling system regualtes glioma cell survival via NfkappaB pathway activiation and BCL-XL-W expression. J Biol Chem 280: 3483-3492.
54. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP et al. (2003). NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 17: 1349-1356.
55. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. (2003). ZAP-70 expression identifies a chronic lymphocytic leukemia sub-type with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951.
56. Wilson KC, Center DM, Cruikshank WW. (2004). The effect of interleukin-16 and its precursor on T-lymphocyte activation and growth. Growth Factors 22: 97-104.
57. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX et al. (1995). Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 181: 1661-1672.
58. Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W. (2003). Cytokkine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol 31: 185-190.